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ORFK13/vFLIP of Kaposi's sarcoma-associated herpesvi-
rus (KSHV) encodes a 188-amino acid protein, which
binds with Iκb kinase gamma subunit (IKKγ) to activate
the NFκB pathway. To gain insight into the changes
induced by K13 in endothelial cells, we retrovirally
expressed ORFK13 in human umbilical vein endothelial
cells (HUVECs) and examined by DNA microarray pat-
terns of genes expression in control retrovirus- and K13
retroviral-infected HUVECs. As expected, expression of
numerous NFκB-targeted genes increased and expression
of a limited number of genes decreased in K13-expressing
HUVECs compared to control. Genes with increased
expression included pro-inflammatory chemokines,
cytokines, and adhesion molecules. Consistent with these
results, K13-expressing HUVECs promoted monocyte
attachment in vitro more effectively than controls, an
observation consistent with immunofluorescent staining
of AIDS-KS tissue showing infiltration of CD68-positive
monocyte/macrophages. These infiltrating CD68-positive
cells displayed moderate expression of VEGF, suggesting
that K13 expression in KSHV-infected cells contributes to
monocyte/macrophages attachment and represents a
source of VEGF for tumor cells. Additionally, retroviral
gene expression of ORFK13 caused a dynamic morpho-
logical change in HUVEC that turned into spindle-like
cells, and altered endothelial formation of vascular struc-
tures on extracellular matrix. In another aspect, K13 retro-
virus induced significant expression of human thymidine
phosphorylase, which is also called platelet-derived
endothelial cell growth factor (PD-ECGF). PD-ECGF can
metabolize 5-fluoro-5-deoxyuridine (5-dFUrd) into 5-
fluorouridine (5-FU), a thymidylate synthase inhibitor.
When cytotoxity was measured, 5-dFUrd selectively killed
K13-expressing HUVECs at low concentrations (0.1–1
μM), which did not affect the survival of control HUVECs.
This observation has potential clinical implications for
the treatment of KSHV-related malignancies where
ORFK13/vFLIP is expressed and responses to current ther-
apy are poor.
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